Science News & Science Current Events
 
Email a Friend Send to a friend
Printer Friendly Print Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence

Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence

April 30, 2008

C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1.

According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched "Your Health Choice" radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is it's high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half.




"Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone," says Dr. Raymond. "C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses."

A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probiotic that is effective in fighting recurrent C. diff-associated disease1 Additionally, an article in the March 2006 issue of Gastroenterology and Hepatology showed that use of S. boulardii provided an almost 50 percent decrease in subsequent recurrence among patients who suffered recurrent CDAD symptoms.2 "Because Florastor (S. boulardii) is a yeast and not a bacteria, it is not killed by the strong antibiotics that are being used to kill the C. diff bacteria, so it survives in the digestive tract," says Dr. Raymond. "When the 'baby' C. diff emerge from their spores, they are greeted by a well-colonized gut, rather than an empty playground."

CDAD is usually indicated by severe abdominal pain, diarrhea with mucous and blood passage, and fever. Dr. Raymond advises those exhibiting these symptoms to see a physician immediately to be tested for the presence of the C. diff toxins and to be prescribed proper antibiotics, since over-the-counter anti-diarrheal agents should be avoided.

"Traditional OTC anti-diarrheal products actually slow down the speed of fluids moving through your bowels, and, in the case of C. diff, keeping the bacteria in the bowels is actually a bad thing," she adds.

Healthcare practitioners are advised to adhere to strict hand-washing policies in offices and hospitals to help prevent the spread of this and other types of bacteria.

Florastor has shown in more than 50 years of extensive international use to be safe and effective, with an estimated 1.7 billion daily doses sold to date. It is mentioned by the World Health Organization (WHO) for use in the management of C.diff-associated disease.3
1McFarland, L.V. (2006). Meta-analysis of probiotics for the prevention of antibiotic- associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology. 101, 812-822.

2Huebner, E.S., & Surawicz, C.M. (2006). Treatment of recurrent Clostridium difficile diarrhea. Gastroenterology and Hepatology. 2, 203-208.

3Saccharomyces boulardii: a valuable adjunct in recurrent Clostridium difficile disease" (1995) WHO Drug Information; 9;(1); 15-16.

Biocodex, Inc.



Related Clostridium Difficile Current Events and Clostridium Difficile News Articles Clostridium Difficile Current Events and Clostridium Difficile News RSS Clostridium Difficile Current Events and Clostridium Difficile News RSS
Is re-emerging superbug the next MRSA?
Loyola physicians warn little-known bacteria Clostridium difficile next emerging disease threat, killing 1,000s in the United State.

Advances in C. difficile research
New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.

The balance shifts
The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers from the University of Sherbrooke in Canada. They report their findings in the June 15 issue of Clinical Infectious Diseases, currently available online.

ASGE issues updated infection control guidelines for gastrointestinal endoscopy
The American Society for Gastrointestinal Endoscopy (ASGE) has updated its infection control guidelines regarding gastrointestinal (GI) endoscopy.

UV lotion lights the way to cleaner facilities
A team of Canadian scientists using a lotion which glows under ultraviolet light have shown that up to a third of patient toilets are not properly cleaned.

MRSA in hospital intensive care -- what's growing where?
Researchers are finding out which bugs grow in intensive care units to develop a novel sampling regime that would indicate the threat of MRSA and other superbugs in the environment, scientists heard today (Monday 31 March 2008) at the Society for General Microbiology's 162nd meeting being held this week at the Edinburgh International Conference Centre.

APIC launches first national C. difficile prevalence study
The Association for Professionals in Infection Control and Epidemiology (APIC) today announced a detailed strategy to combat Clostridium difficile-associated disease (CDAD).

Confronting the challenge of antimicrobial resistance
Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.

C-diff infection 4 times more likely to kill patients with inflammatory bowel disease
Clostridium difficile infection is four times more likely to kill patients with inflammatory bowel disease, suggests research published ahead of print in the journal Gut.
More Clostridium Difficile Current Events and Clostridium Difficile News Articles


Clostridium difficile (Current Topics in Microbiology and Immunology)

Clostridium difficile has been recognized as the cause of a broad spectrum of enteric disease ranging from mild antibiotic-associated diarrhea to pseudomembranous colitis. This volume gives new insights into the microbiology, diagnostics and epidemiology of Clostridium difficile and describes recent strategies in treatment of diseases caused by this agent. Main parts of the volume are devoted to...

Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function.(Case Report) : An article from: Southern Medical Journal
by Sangita Aradhyula, Farrin A. Manian, Saad A.S. Hafidh, Saqib S. Bhutto, Martin A. Alpert

This digital document is an article from Southern Medical Journal, published by Thomson Gale on May 1, 2006. The length of the article is 2139 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Consider newer therapies to treat new strain of C. difficile.(infectious Diseases): An article from: Pediatric News
by John R. Bell

This digital document is an article from Pediatric News, published by Thomson Gale on May 1, 2007. The length of the article is 867 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Consider newer...



Clostridium Difficile - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and...

Recognizing and Managing Clostridium Difficile-Associated Diarrhea.: An article from: MedSurg Nursing
by Joanne M. Miller, Jane C. Walton, Lydia L. Tordecilla

This digital document is an article from MedSurg Nursing, published by Jannetti Publications, Inc. on December 1, 1998. The length of the article is 5268 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.From the...

Levofloxacin, cefazolin boost risk for C. difficile diarrhea.(Clostridium difficile): An article from: Internal Medicine News
by Mitchel L. Zoler

This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2004. The length of the article is 571 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Leukemoid reactions complicating colitis due to clostridium difficile.(Original Article): An article from: Southern Medical Journal
by Mark A. Marinella, Steven D. Burdette, Roger Bedimo, Ronald J. Markert

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on October 1, 2004. The length of the article is 4180 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Clostridium difficile--associated diarrhea and chronic renal insufficiency.: An article from: Southern Medical Journal
by Khurshid Yousuf, Mohammad G. Saklayen, Ronald J. Markert, Christopher J. Barde, Narasimh Gopalswamy

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on July 1, 2002. The length of the article is 1945 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Clostridium difficile-associated disease in New Jersey Hospitals, 2000-2004 [1].(DISPATCHES): An article from: Emerging Infectious Diseases
by Esther T. Tan, Corwin A. Robertson, Shereen Brynildsen, Eddy Bresnitz, Christina Tan, Clifford McDonald

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on March 1, 2007. The length of the article is 2303 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Virulent outbreaks worry experts: new epidemic strain of Clostridium difficile has been isolated in nine states and Canada.(News): An article from: Skin & Allergy News
by Betsy Bates

This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2005. The length of the article is 817 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com